Considering The EU Launch Of Biosimilar For Remicade, Merck’s 2nd Largest Drug, Does The Company Face Meaningful EPS Decline In 2016?

-7.29%
Downside
132
Market
122
Trefis
MRK: Merck logo
MRK
Merck

Merck’s EPS Impact Due To Remicade Biosimilar Competition In 2016 Is Insignificant, < 2%


Merck_Q7

Have more questions about Merck? See the links below.

Relevant Articles
  1. At $100 Does Merck Stock Have Room For Growth?
  2. Should You Pick Merck Stock Over Coca-Cola?
  3. Should You Buy Merck Stock After An Upbeat Q2?
  4. How Has Merck Stock Performed During The 2022-23 Inflation Shock?
  5. Is Merck Stock A Better Pick Over ABBV?
  6. Should You Buy Merck Stock At $120?

Notes:

1) The purpose of these analyses is to help readers focus on a few important things. We hope such lean communication sparks thinking, and encourages readers to comment and ask questions on the comment section, or email content@trefis.com
2) Figures mentioned are approximate values to help our readers remember the key concepts more intuitively. For precise figures, please refer to our complete analysis for Merck

 

See More at Trefis | View Interactive Institutional Research (Powered by Trefis)

Get Trefis Technology